Demecolcine Hydrobromide Salt

API STANDARDS

Product Details

CAT No.# CS-T-51836
Category API Standards
CAS 1246817-95-7
Molecular Weight 452.34
Molecular Formula C21H26BrNO5
Purity: >98%
Melting Point: 224-229
Solubility: Dichloromethane, DMSO, Methanol
Appearance: Pale Yellow Solid
Synonyms: (10S)-3,4,5,14-tetramethoxy-10- (methylamino)2,4,6,11,14-hexaen-13-one hydrobromide
Application Notes: An antimitotic agent that disrupts microtubles by binding to tubulin and preventing its polymerization. Stimulates the intrinsic GTPase activity of tubulin. Induces apoptosis in several normal and tumor cell lines and activates the JNK/SAPK signaling pathway.
References: Lunduena, R.F., et al.: Curr. Opin. Cell Biol., 4, 53 (1992), Ceccatelli, S., et al.: Neuroreport, 8, 3779 (1997), Want, T.H., et al.: J. Biol. Chem., 273, 4928 (1998), Andreu, J.M., et al.: Biochemistry, 37, 8356 (1998), Jordan, A., et al.: Med. Res. Rev
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
CNC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC.Br



This page contains information about Demecolcine Hydrobromide Salt Cas 1246817-95-7 and its API Standards.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."